Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.

Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS.

Sci Signal. 2009 Dec 15;2(101):ra82. doi: 10.1126/scisignal.2000446.


An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS.

Cancer Discov. 2011 Oct;1(5):442-56. doi: 10.1158/2159-8290.CD-11-0102. Epub 2011 Sep 15. Erratum in: Cancer Discov. 2012 Feb;2(2):290-1.


The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.

Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12932-7. doi: 10.1073/pnas.0906606106. Epub 2009 Jul 22.


EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7.


Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.

Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.

Clin Exp Pharmacol Physiol. 2013 Jan;40(1):13-21. doi: 10.1111/1440-1681.12026.


Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.

Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MC, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch A, Heppner FL, Yonekawa Y, Merlo A, Frei K, Mariani L, Hofer S.

Mol Cancer Ther. 2011 Jun;10(6):1102-12. doi: 10.1158/1535-7163.MCT-11-0048. Epub 2011 Apr 6.


Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.

Acquaviva J, Jun HJ, Lessard J, Ruiz R, Zhu H, Donovan M, Woolfenden S, Boskovitz A, Raval A, Bronson RT, Pfannl R, Whittaker CA, Housman DE, Charest A.

Cancer Res. 2011 Dec 1;71(23):7198-206. doi: 10.1158/0008-5472.CAN-11-1514. Epub 2011 Oct 10.


SREBP-1 activation by glucose mediates TGF-β upregulation in mesangial cells.

Uttarwar L, Gao B, Ingram AJ, Krepinsky JC.

Am J Physiol Renal Physiol. 2012 Feb 1;302(3):F329-41. doi: 10.1152/ajprenal.00136.2011. Epub 2011 Oct 26.


Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.

Schulte A, Liffers K, Kathagen A, Riethdorf S, Zapf S, Merlo A, Kolbe K, Westphal M, Lamszus K.

Neuro Oncol. 2013 Oct;15(10):1289-301. doi: 10.1093/neuonc/not093. Epub 2013 Jul 21.


Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.

Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9406-11. doi: 10.1073/pnas.1511759112. Epub 2015 Jul 13.


An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.


IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway.

Smith TM, Gilliland K, Clawson GA, Thiboutot D.

J Invest Dermatol. 2008 May;128(5):1286-93. Epub 2007 Nov 8.


Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS.

Cancer Res. 2006 Aug 15;66(16):7864-9.


EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.

Zhu H, Cao X, Ali-Osman F, Keir S, Lo HW.

Cancer Lett. 2010 Aug 1;294(1):101-10. doi: 10.1016/j.canlet.2010.01.028. Epub 2010 Feb 13.


Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas.

Zhang KL, Han L, Chen LY, Shi ZD, Yang M, Ren Y, Chen LC, Zhang JX, Pu PY, Kang CS.

Cancer Lett. 2014 Jan 1;342(1):139-49. doi: 10.1016/j.canlet.2013.08.043. Epub 2013 Sep 3.


The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.

Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG.

Neoplasia. 2009 May;11(5):448-58, 2 p following 458.


InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.

Ma Y, Tang N, Thompson RC, Mobley BC, Clark SW, Sarkaria JN, Wang J.

Clin Cancer Res. 2016 Apr 1;22(7):1767-76. doi: 10.1158/1078-0432.CCR-15-1677. Epub 2015 Nov 11.


Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.

Huang Y, Chen Y, Mei Q, Chen Y, Yu S, Xia S.

Oncol Rep. 2013 Jun;29(6):2486-92. doi: 10.3892/or.2013.2357. Epub 2013 Mar 22.


Supplemental Content

Support Center